Breaking News

Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis U.S. Small Business Administration Applications are Required before FEMA Individual Assistance can be Provided Apply for Assistance Even If You Are Unsure Department of Labor cites Dollar Tree again for endangering workers, continuing company’s lengthy history of workplace safety violations False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents Administrator Samantha Power Meets with Foreign Minister of Sri Lanka Ali Sabry | Readout FIS Challenges Nearly 200 Startups to Pitch their Boldest Ideas in First APAC Fintech Competition

Issued: Thursday 4 February 2010, London UK

GSK today announces the appointment of Philippe Fauchet as President of GSK Japan. Philippe will report to Marc Dunoyer, who takes the new role as Chairman of GSK Japan. Marc will continue to take overall leadership responsibility for GSK’s Pharmaceuticals business across the Asia Pacific/ Japan Region.

Philippe joins GSK from Sanofi Aventis where he was Senior Vice President, Business Development. He joined Sanofi in 1996, and headed up the Eastern Europe region from 1997, before becoming Vice President, Eastern Europe for Sanofi-Synthélabo in 1999. Philippe Fauchet took over as head of Sanofi-Synthélabo’s Japanese operations in June 2001 and was appointed as Senior Vice President Pharmaceuticals Operations, Japan in May 2005.

Philippe is a graduate of HEC (Ecole des Hautes Etudes Commerciales), and also holds a law degree. He joined Roussel Uclaf in 1984, and held a number of posts in France, Japan and Korea, before becoming Vice President of the Asia-Pacific region for Hoechst Marion Roussel in 1995.

Marc Dunoyer, GSK’s President of Asia Pacific and Chairman of Japan, said: “The depth of knowledge and experience Philippe gained through previous roles in Japan, his general business and commercial acumen and his proven leadership skills make him ideally suited to drive the growth of this key business. Over the next five years we have the potential to launch between 30 and 40 products in Japan and I look forward to working with Philippe to maximise this opportunity.”

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

GlaxoSmithKline Enquiries:


UK Media enquiries:

Philip Thomson

(020) 8047 5502


Claire Brough

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502


Jo Revill

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(919) 483 2839



European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564


Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill Baxter

(215) 751 7002

Source link